An observational study in Chronic Pain and Acute Pain, sponsored by Insel Gruppe AG, University Hospital Bern. Not yet recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Chronic Pain with a site in Switzerland — 9 open to participants now, 9 under way, none of them phase 3. Chronic Pain · Switzerland.
Among the 43 studies in Chronic Pain with a site in Switzerland, this one is the 5th largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2026, is one of 21 observational ones, and was the 43rd registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →9 of the 43 studies in Chronic Pain with a site in Switzerland are open now. Recruiting first, the newest first:
Medtronic · Sites in Switzerland, United States, Belgium and 1 more country
Ages 18+
Cosima Locher · Sites in Switzerland
Ages 18+
Sobet AG · Sites in Switzerland, Austria
Ages 18–99
Abbott Medical Devices · Sites in Switzerland, United States, Australia and 6 more countries
Ages 18+
Boston Scientific Corporation · Sites in Switzerland, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 120 across 755 observational studies indexed under Chronic Pain.
Median enrollment 106 across the 22 interventional studies, 168 across the 21 observational. Of the 33 that completed or were terminated, 3 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 43 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 3 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Pain with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851326Sobet AGLow-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Therapy-Resistant Myofascial Pain Syndrome | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Chronic Pain with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational registry is to systematically collect and analyse real-world clinical and patient-reported data in individuals receiving treatment for acute and chronic pain. The main questions it aims to answer are: How do pain intensity, functional status, and quality of life evolve over time in patients with acute and chronic pain? How are different routine clinical treatment approaches associated with patient-reported outcomes in real-world clinical practice? Participants already receiving standard care for pain management will have routine clinical data recorded as part of their treatment and will be asked to complete standardized questionnaires on pain intensity, functional status, and quality of life at multiple time points during treatment and follow-up. Data are collected using a secure electronic system and are pseudonymised prior to analysis in accordance with Swiss data protection regulations.
This prospective, observational registry study aims to establish a standardized, multidomain digital assessment platform for patients with acute and chronic pain within routine outpatient care at the University Hospital Bern. The registry is designed as a scalable national infrastructure with planned expansion to additional Swiss pain clinics. The primary objective is to evaluate feasibility, acceptability, and data quality of a digital baseline assessment integrating validated patient-reported outcome measures (PROMs) across pain, functional, psychological, sleep, and quality-of-life domains. Secondary objectives include the description of baseline patient profiles, exploration of longitudinal outcomes at 6, 12, 18, and 24 months, assessment of operational feasibility of follow-up assessments, and investigation of sex- and gender-related differences. In addition, optional treatment-triggered follow-up modules may be used after therapeutic interventions to capture short-term outcomes, side effects, and patient-reported treatment satisfaction. Data are collected prospectively via REDCap and include both routinely documented clinical data and additional patient-reported outcomes. The study duration is 36 months, including a 12-month recruitment phase and 24 months of follow-up per participant.
The study population consists of patients referred for interdisciplinary outpatient assessment and management of acute and chronic pain. The registry includes paediatric and adult patients of all genders across the full spectrum of acute and chronic pain conditions in routine clinical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled in the Swiss Pain Registry. The cohort includes patients with acute and chronic pain receiving routine clinical care. No intervention is assigned; data are collected observationally through clinical documentation and patient-reported outcome measures over a follow-up period of up to 24 months.
Feasibility of baseline assessment
Feasibility is defined as the proportion of eligible participants who complete the full multidomain digital baseline assessment across all predefined domains.
Time frame: Baseline (at enrollment)
Data quality of baseline assessment
Data quality will be evaluated by completeness of core variables of the multidomain digital baseline assessment (percentage of missing data at item and domain level).
Time frame: Baseline (at enrollment)
Pain intensity
Pain intensity measured using the Brief Pain Inventory (BPI). The BPI uses numeric rating scales from 0 to 10, where higher scores indicate greater pain intensity.
Time frame: Baseline, 6, 12, 18, 24 months
Pain interference
Pain interference measured using the Brief Pain Inventory (BPI). The BPI uses numeric rating scales from 0 to 10, where higher scores indicate greater pain interference.
Time frame: Baseline, 6, 12, 18, 24 months
Neuropathic pain screening
Neuropathic pain symptoms assessed using the Douleur Neuropathique 4 (DN4) questionnaire. Total scores range from 0 to 10, with higher scores indicating greater likelihood of neuropathic pain.
Time frame: Baseline, 6, 12, 18, 24 months
Neuropathic pain symptom profile
Neuropathic pain symptom profile assessed using the Neuropathic Pain Symptom Inventory (NPSI). Total scores range from 0 to 100, with higher scores indicating more severe neuropathic pain symptoms.
Time frame: Baseline, 6, 12, 18, 24 months
Functional disability
Functional disability assessed using the Oswestry Disability Index (ODI). Total scores range from 0 to 100, with higher scores indicating greater disability.
Time frame: Baseline, 6, 12, 18, 24 months
Work ability
Work ability assessed using the Work Ability Index (WAI). Total scores range from 7 to 49, with higher scores indicating better work ability.
Time frame: Baseline, 6, 12, 18, 24 months
Psychological distress
Psychological distress (anxiety, depression) assessed using the Patient Health Questionnaire-4 (PHQ-4). Total scores range from 0 to 12, with higher scores indicating greater anxiety and depressive symptoms.
Time frame: Baseline, 6, 12, 18, 24 months
Pain catastrophizing
Pain catastrophizing assessed using the Pain Catastrophizing Scale (PCS). Total scores range from 0 to 52, with higher scores indicating greater catastrophizing.
Time frame: Baseline, 6, 12, 18, 24 months
Sleep quality
Sleep quality assessed using the Bernese Sleep Health Questionnaire (BSHQ). Higher scores indicate worse sleep quality.
Time frame: Baseline, 6, 12, 18, 24 months
Health-related quality of life
Health-related quality of life assessed using the World Health Organization Quality of Life - BREF (WHOQOL-BREF). Total scores range from 0 to 100, with higher scores indicating better quality of life.
Time frame: Baseline, 6, 12, 18, 24 months
Global patient-reported improvement
Global improvement measured using the Patient Global Impression of Change (PGI-C). The PGI-C is a 7-point scale ranging from "very much worse" to "very much improved".
Time frame: 6, 12, 18, 24 months
Follow-up completion and adherence
Completion rates of PROM assessments, adherence to follow-up schedules, and workflow integration indicators including proportion of home versus clinic completion and completion time.
Time frame: 6, 12, 18, 24 months
Post-intervention pain intensity and interference
Pain intensity and interference assessed approximately one week after therapeutic interventions using the Brief Pain Inventory (BPI; 0-10 scale, higher scores indicate worse pain and interference).
Time frame: Approximately 1 week after intervention (post-intervention follow-up; variable depending on clinical trigger)
Post-intervention side effects and adverse events
Patient-reported side effects and adverse events collected approximately one week after intervention using structured questionnaire items.
Time frame: Approximately 1 week after intervention (post-intervention follow-up; variable depending on clinical trigger)
Post-intervention treatment satisfaction and perceived effectiveness
Patient-reported satisfaction, perceived effectiveness, and acceptability of the intervention assessed approximately one week after treatment using structured questionnaire items.
Time frame: Approximately 1 week after intervention (post-intervention follow-up; variable depending on clinical trigger)
Plan to share: Undecided — Individual participant data (IPD) collected within this registry are currently not planned for routine sharing with external researchers. Any future sharing of de-identified or coded datasets will be considered on a case-by-case basis and will require appropriate ethical approval, data transfer agreements, and compliance with applicable Swiss data protection regulations and institutional policies. No direct identifiers will be shared at any time.
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Aug 2029, 37 months later.
Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 37 months is above that.
Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →